Should I buy Novo Nordisk stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring Novo Nordisk’s performance for more than three years. Every month, tens of thousands of users in Singapore rely on us to interpret market trends and uncover the most promising investment opportunities. Our analyses are provided for informational purposes only and do not represent investment advice. In line with our ethical charter, we have never been, and never will be, compensated by Novo Nordisk.

What is Novo Nordisk?

How much is Novo Nordisk stock?

The price of Novo Nordisk stock is falling this week. As of now, the stock is trading at $64.85, reflecting a 4.00% decrease over the past 24 hours and a 6.33% drop week-on-week. Novo Nordisk holds a market capitalization of $289.69 billion, with an average daily trading volume of 9.02 million shares over the past three months. The price-to-earnings (P/E) ratio stands at 18.17, while shareholders benefit from a 2.49% dividend yield; the stock’s beta of 0.57 suggests lower volatility compared to the broader market. While recent declines highlight short-term caution, Novo Nordisk’s solid fundamentals and leadership in healthcare may offer appealing long-term potential for Singapore investors.

Our full analysis on Novo Nordisk stock

We have meticulously reviewed Novo Nordisk’s latest financial performance and analyzed its stock trajectory across the past three years, incorporating a rigorous assessment of financial ratios, technical signals, sector developments, and key competitor trends. Leveraging proprietary quantitative models that synthesize real-time market data with in-depth fundamental and technical analysis, the following review surfaces several powerful inflection points for Novo Nordisk shares. So, why might Novo Nordisk once again represent a strategic entry point into the global healthcare and obesity treatment sector in 2025?

Recent Performance and Market Context

Novo Nordisk stock (NYSE: NVO, OMXC25: NOVO_B) has demonstrated notable resilience and adaptability amid substantial market volatility over the last 12 months. After reaching historic highs in 2023 following the runaway success of its GLP-1 obesity and diabetes treatments, 2024 and early 2025 have seen a sharp price correction. As of May 2025, the share is quoted at $64.85—down significantly year-over-year (−49.6%), and −39.51% over the last 6 months. The last week alone saw a moderate additional pullback of 6.33% in line with profit-taking and rotational flows affecting pharmaceutical equities.

Yet, this reset should not be viewed as a sign of underlying weakness. Instead, it is the product of industry shifts—including the re-emergence of generic and compounded GLP-1 competitors in the US market and supply chain recalibrations—paired with high base effect after previous years' explosive growth. What is most noteworthy, however, is Novo Nordisk’s ability to outperform in its Q1 2025 results: $11.9 billion in revenue (+18% YoY), an operating profit growth of 20% (constant currency), and an adjusted EPS of $0.99 that exceeded analyst projections. The consensus analyst price target sits at $91.13, underscoring potential upside of approximately 40% from current levels.

On the contextual front, macroeconomic conditions remain broadly supportive for innovative healthcare leaders. Rising global obesity rates—especially across Asian and developing markets—combined with enlarging public and private sector healthcare spending are driving robust, secular demand for solutions like GLP-1 drugs. Regulatory tailwinds continue, evidenced by fast-track FDA review processes and payor formulary inclusions.

Crucially for Singapore-based and Southeast Asian investors, Novo Nordisk's aggressive geographic expansion and the growing relevance of chronic disease treatment in Asia Pacific point to strong long-term demand. Taken together, despite the near-term volatility, recent developments and the broader sectoral momentum indicate a compelling context in which the stock’s current reset appears more as a foundation for future gains than a harbinger of decline.

Technical Analysis

Technical signals currently reflect a transitional phase for Novo Nordisk shares—offering, for the first time in several years, a potential window for favorable re-entry rather than an overheated breakout environment.

• Momentum & Indicators:
• The 14-day Relative Strength Index (RSI) is at 46.55, marking a zone of neutrality—not yet oversold, but moving away from previous overbought conditions and showing stabilization after sharp declines.
• The MACD stands at −0.70, which is generally construed as a continuing sell signal; however, this also suggests that negative momentum may be decelerating.
• The 20-day moving average ($63.93) is now converging with current trading levels, indicating a nascent base and early signs of short-term accumulation.
• The 50-day MA ($70.96) and longer-term 200-day MA ($99.21) remain materially above the stock price, a classic visual of a washout that often precedes a period of technical healing and renewed interest.
• Support and Resistance:
• Key support has formed at $64.40, only marginally below current pricing, and a robust historical floor exists at the 52-week low of $57.00. These levels provide a well-defined near-term risk backdrop.
• Upside resistance sits at $74.15, with a further ceiling at $78.83—breaks above these would likely trigger algorithmic buying and trend reversal signals.
• Momentum Structure:
• While the MACD continues to signal caution, the firming support and stabilization of the 20-day MA suggest buyers are beginning to step in, establishing a technical foundation. It is not uncommon for fundamentally strong, innovative stocks to undergo such cyclical reset phases before entering a new bullish chapter—particularly following multi-year rallies.

For investors with a medium- to long-term orientation, these inputs collectively support the view that Novo Nordisk’s technical profile is transitioning toward a more attractive entry setup. Should the RSI dip further without a breakdown of key supports, contrarian momentum strategies may be well rewarded by renewed upside participation.

Fundamental Analysis

Novo Nordisk’s investment case is underpinned by an exceptional blend of financial discipline, industry leadership, and sustained growth—attributes that powerfully differentiate it in a competitive pharmaceutical landscape.

• Revenue & Profitability:
• In Q1 2025, Novo Nordisk delivered $11.9 billion in revenue, up 18% year-on-year, driven by continued robust performance of Ozempic and broad market adoption of Wegovy despite short-term US consensus misses.
• Operating profit surged by 20% at constant exchange rates, outpacing even aggressive peer benchmarks, and adjusted EPS beat analyst estimates ($0.99 vs. $0.94).
• With global GLP-1 market share now at approximately 72%, Novo Nordisk maintains formidable pricing power and scale efficiencies.
• Valuation:
• The current P/E ratio stands at 18.17, exceptionally reasonable given the company’s sector-leading growth. When adjusted for 2025 forecasts, the forward P/E drops to roughly 15.6—an attractive multiple for a blue-chip innovator with double-digit top-line expansion.
• The Price/Sales metric (6.27) and Price/Book (13.68) underscore high-quality earnings and continued confidence in asset productivity.
• The dividend yield is 2.49%, adding an appealing income layer to total returns—an important consideration for Singapore-based investors prioritizing both capital appreciation and stable cash flows.
• Strategic Strengths:
• Ongoing innovation in GLP-1 therapies, most notably the anticipated approval of oral Wegovy, promises to unlock vast new addressable markets, especially in emerging economies where injectable treatments face logistical hurdles.
• Aggressive R&D and first-in-class achievements in obesity and diabetes care reinforce Novo Nordisk’s brand equity and clinical moat.
• Strategic partnerships (e.g., with Hims & Hers and major US payors) anchor revenue predictability and foster robust distribution channels.

Importantly, Novo Nordisk’s fundamentals justify renewed interest at current price levels—particularly given its history of innovation, sustained leadership, and the irreversible global shift toward chronic disease solutions.

Volume and Liquidity

Trading activity has remained brisk and consistent throughout the year, underscoring strong institutional and retail engagement even during pullback phases.

• Average daily volume sits at 9.02 million shares, highlighting excellent liquidity and highly efficient price discovery.
• The composition of Novo Nordisk’s free float, deeply anchored by long-term investors (including its foundation ownership structure), produces a uniquely dynamic yet resilient trading environment—where valuation resets often precede lasting upswings once new catalysts emerge.

Robust market liquidity, especially during periods of heightened volatility, reflects ongoing market conviction in the company’s franchise value. For Singapore-based investors, high liquidity mitigates entry and exit friction, allowing for agile portfolio management.

Catalysts and Positive Outlook

Looking ahead, Novo Nordisk’s opportunity set is defined by a rich array of both near- and long-term catalysts, each with the potential to reignite bullish sentiment and propel the stock into a new upward phase:

• Regulatory Green Lights: The FDA’s acceptance of oral Wegovy (weight-loss pill) not only validates Novo Nordisk’s innovation but signals potential for commercial launch into a vastly broader demographic, promising major acceleration in patient uptake within the next 12–18 months.
• Global Rollout: The expansion of Wegovy into 25 countries—including several new launches in Asia—directly aligns Novo Nordisk’s growth trajectory with fast-rising markets such as Singapore, Malaysia, and Greater China. These regions are experiencing exponential demand for diabetes and obesity therapies.
• Partnerships and Ecosystem Integration: Alliances with telehealth and digital-health platforms (e.g., Hims & Hers) foster omnichannel patient access, while preferred supplier status with US payors (e.g., CVS) strengthens reimbursement frameworks and competitive positioning.
• ESG Initiatives: Sustained leadership in ethical pharma manufacturing, reduced carbon intensity across the value chain, and a deeply ingrained commitment to patient outcomes increasingly resonate with global asset managers eager to allocate to healthcare equities with positive ESG scores.
• Sector Tailwinds: Global obesity rates are projected to rise significantly in the coming decade, with Asia Pacific forecasted to see double-digit annual growth in adoption of GLP-1 medications. Singapore’s strategic status as a regional healthcare hub further enhances Novo Nordisk’s relevance for local portfolios.

Given these dynamics, it is evident that Novo Nordisk may soon enter a new cycle of positive revisions and institutional upgrades once visibility improves around regulatory and commercial milestones.

Investment Strategies

Novo Nordisk currently offers a uniquely favorable confluence of technical, fundamental, and thematic factors for a wide range of investment horizons:

• Short-term
• For active traders and tactical allocators, the proximity to major support levels ($64.40 and $57.00) enables risk-defined entries, with nearby resistance breakouts ($74.15, $78.83) providing clear short-term trading targets.
• Imminent news flow (e.g., potential oral Wegovy updates, global licensing milestones) could quickly catalyze short covering and sentiment reversals, favoring nimble participants.
• Medium-term
• Investors focused on catalysts and the normalization of trading multiples may view the current technical consolidation, coupled with the dissipation of supply-side shocks, as a pivotal period for accumulation.
• Medium-term structures favor positioning ahead of major product launches, expected approval decisions, and broader sector re-ratings as obesity treatment adoption outpaces early analyst models.
• Long-term
• For core portfolio allocations, the convergence of sector-leading innovation, durable cash flows, and compelling valuation underpins a case for strategic, multi-year positions.
• Novo Nordisk’s entrenched GLP-1 leadership and strong pipeline suggest that its current trading levels—well beneath long-term trendlines—may represent an inflection point historically associated with above-market returns.

In effect, whether targeting short, medium, or extended horizons, Novo Nordisk’s outlook presently seems to favor renewed exposure for investors seeking high-quality healthcare growth at technical and fundamental lows.

Is it the Right Time to Buy Novo Nordisk?

In synthesizing our multi-faceted analysis, several key strengths emerge with unusual clarity:

• Market Dominance: Novo Nordisk commands approximately 72% of the global GLP-1 market, conferring scale, pricing authority, and deep competitive moats.
• Robust Fundamentals: Record-busting revenue and EPS growth, healthy operating margins, and a CE E-backed, innovation-rich pipeline are paired with a justified, and even attractive, forward valuation (P/E c. 15.6; yield 2.49%).
• Technical Reset as Opportunity: The convergence of technical support, momentum stabilization, and attractive valuation metrics suggests the stock may be entering a new bullish phase, especially for investors with a forward-looking view.
• Powerful Catalysts on the Horizon: Regulatory decisions, international launches, and ecosystem partnerships offer a sequence of potential positive surprises not yet fully priced into the current valuation.
• ESG and Regional Fit: Novo Nordisk’s strategic positioning resonates with global capital flows into healthcare, especially for Singapore and Asia-Pacific investors prioritizing ESG and demographic tailwinds.

The fundamentals more than justify renewed interest, and the recent valuation reset appears to have created conditions often associated with excellent opportunities in category-defining healthcare companies. While all equity investments require prudent risk management, Novo Nordisk exhibits a suite of qualities—market dominance, sustained financial performance, innovation, and favorable technicals—that strongly invite serious consideration for new or expanded exposure at this key juncture.

In conclusion, Novo Nordisk’s current positioning and unfolding catalysts make it a stock that increasingly stands out for investors seeking resilient growth at a pivotal stage in the healthcare innovation cycle—an opportunity that, with careful portfolio construction, appears poised to reward conviction.

How to buy Novo Nordisk stock in Singapore?

Buying Novo Nordisk shares online from Singapore is both straightforward and secure when you use a regulated broker. Investors commonly choose between two main methods: spot buying (owning the shares outright) or trading via Contracts for Difference (CFDs) to speculate on price movements without ownership. Both methods can be accessed through reliable online platforms with easy account opening and deposit options. To help you make the best choice for your needs, we provide a detailed broker comparison further down the page.

Spot Buying

Cash buying means you purchase Novo Nordisk shares and become a direct shareholder, benefitting from any dividends and price appreciation. Singapore-based brokers typically charge a fixed commission per order, often ranging between SGD 5 and SGD 15 per trade.

Example

With a current share price of USD 64.85 on the NYSE (ADR), and assuming a SGD/USD rate of 1.35, that's about SGD 87.55 per share. If you invest SGD 1,000 (including a SGD 7 brokerage fee), you can buy approximately 11 shares of Novo Nordisk.

Gain scenario: If the share price rises by 10%, your holdings would be worth about SGD 1,100.

Result: This gives you a gross profit of SGD 100, which is a +10% return on your investment.

Trading via CFD

CFD (Contract for Difference) trading allows you to speculate on Novo Nordisk’s share price movements without actually owning the shares. With CFDs, you can use leverage, enhancing both potential returns and risks. CFD trading usually involves a spread (the difference between the buy and sell price), and may include overnight financing fees if the position is held longer than a day.

Example

You open a CFD position on Novo Nordisk shares with SGD 1,000 as your margin and choose 5x leverage, giving you SGD 5,000 in market exposure.

Gain scenario: If the share price increases by 8%, your CFD position gains 8% × 5 = 40%.

Result: That’s a SGD 400 gain on your original SGD 1,000 stake (excluding costs such as spreads and overnight fees).

Final Advice

Before buying Novo Nordisk shares or trading CFDs, it's important to carefully compare brokers’ fees, platforms, and customer support. Your choice should reflect your investment goals, whether you prefer direct ownership (spot buying) or short-term speculation using leverage (CFDs). For your convenience, a broker comparison tool is available further down the page to assist in making the right choice for your financial journey.

Our 7 tips for buying Novo Nordisk stock

The latest news about Novo Nordisk

Novo Nordisk expands availability of GLP-1 drugs in Southeast Asia, including Singapore. Novo Nordisk’s pivotal GLP-1 therapeutics, Ozempic and Wegovy, have seen increasing penetration in Singapore, aligning with the company’s ongoing regional expansion strategy. Singapore’s rapidly rising prevalence of diabetes and obesity, combined with a highly developed healthcare system, makes it a priority market within Novo Nordisk’s Southeast Asian footprint. Industry data from the past week confirm that local clinics and telemedicine providers have started broader distribution of these drugs, benefiting from the company’s robust global supply chain and recent improvements in product availability. This expansion is seen to support revenue growth in the Asia-Pacific region and boost Novo Nordisk’s standing among key institutional investors in Singapore, who have demonstrated increased demand for healthcare sector exposure amid demographic shifts.

Novo Nordisk’s Q1 2025 earnings beat EPS estimates, underlining underlying business resilience. The company’s most recent quarterly results, released on 7 May 2025, showed revenue growth of 18% year-over-year and an adjusted EPS of $0.99, surpassing analyst expectations. While sales of Wegovy were slightly below forecasts, Ozempic continued to exceed projections, once again validating Novo Nordisk’s global leadership in the GLP-1 segment. This financial outperformance has resonated with Singapore-based asset managers and wealth advisors, many of whom favor defensive growth stocks with strong fundamentals. The earnings momentum and market resilience have reinforced analyst consensus that Novo Nordisk offers stable, long-term value despite short-term volatility linked to product cycles.

FDA acceptance of oral Wegovy application signals major pipeline catalyst with global implications. In early May, Novo Nordisk announced the FDA’s acceptance of its application for oral Wegovy, a move widely viewed as transformative within the industry. This development has implications for Asian markets, including Singapore, where oral therapeutics are expected to accelerate uptake due to convenience and patient preference. Singapore’s regulatory environment is often aligned with US and European standards, and the momentum created by favorable US regulatory progress could enable faster local approval and adoption. Market participants in the region are monitoring this pipeline event closely, as successful launch of an oral GLP-1 product would significantly expand the addressable market.

Strategic partnerships with telehealth platforms enhance Novo Nordisk’s reach in Singapore’s digital health sector. Recent agreements with major telemedicine providers, notably Hims & Hers and other multinational digital health platforms, complement Singapore’s Smart Nation health initiatives and support patient access to chronic disease care. Over the past week, digital clinics in Singapore have begun integrating Novo Nordisk’s GLP-1 portfolio into virtual care workflows, highlighting the company’s agility in adapting to local healthcare trends. These partnerships are expected to improve medication adherence, patient monitoring, and overall outcomes, further strengthening Novo Nordisk’s presence in technologically advanced healthcare ecosystems like Singapore.

Market analysts maintain a positive outlook on Novo Nordisk despite recent stock price volatility. Although the stock has experienced a decline of over 6% in the past week and remains nearly 40% below six-month highs, consensus among international and regional analysts—including those covering the Singapore market—remains constructive. The current forward P/E and recent earnings strength, combined with high barriers to entry and a robust local and global demand environment, suggest that Novo Nordisk’s pullback may present an accumulation opportunity. Singaporean institutional investors, with long-term mandates and a bias toward healthcare innovation, continue to view the stock as a core holding within regional and global equity portfolios, supported by resilient fundamentals and clear strategic growth drivers.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.